For research use only. Not for therapeutic Use.
GSK106 is an inactive control for the selective PAD4 inhibitors, GSK484 and GSK199[1].
| Catalog Number | R065571 |
| CAS Number | 1652591-82-6 |
| Synonyms | (3-aminopiperidin-1-yl)-[2-(1-ethylindol-2-yl)-3-methylbenzimidazol-5-yl]methanone;hydrochloride |
| Molecular Formula | C24H28ClN5O |
| Purity | ≥95% |
| InChI | InChI=1S/C24H27N5O.ClH/c1-3-29-20-9-5-4-7-16(20)13-22(29)23-26-19-11-10-17(14-21(19)27(23)2)24(30)28-12-6-8-18(25)15-28;/h4-5,7,9-11,13-14,18H,3,6,8,12,15,25H2,1-2H3;1H |
| InChIKey | VRPFLFUQMWOJAT-UHFFFAOYSA-N |
| SMILES | CCN1C2=CC=CC=C2C=C1C3=NC4=C(N3C)C=C(C=C4)C(=O)N5CCCC(C5)N.Cl |
| Reference | [1]. Lewis HD, et al. Inhibition of PAD4 activity is sufficient to disrupt mouse and human NET formation. Nat Chem Biol. 2015 Mar;11(3):189-91. |
